Table 2 Siglec-directed therapeutics for tumor
From: The intriguing roles of Siglec family members in the tumor microenvironment
Siglec | Drug | Tumor type | Modality | Therapeutic strategy | Phase | Refs/Trial ID |
|---|---|---|---|---|---|---|
Siglec-2 (CD22) | Epratuzumab | B cell lymphoma | MoAb | Inhibits the cis SA-Siglec-2 interaction for the induction of B cell signal transduction and caspase-dependent apoptosis | II | NCT00906841 |
Inotuzumab ozogamicin | B cell lymphoma | MoAb | Causes cell death by inducing double-strand DNA breaks | I/II | NCT01363297 NCT01564784 | |
DT2219 | Refractory B-lineage leukemia or lymphoma | BsAb | Inhibits the protein synthesis and apoptosis | I/II | NCT02370160 | |
CD22-CAR-T | Follicular lymphoma, ALL, NHL, Large cell lymphoma | CAR T | Recognises specific antibodies from tumour cells and targets them | I | NCT02315612 | |
Siglec-3 (CD33) | lintuzumab | AML | MoAb | Induces cell death by complement and/or antibody-directed cellular cytotoxicity or as a direct effect of engaging the CD33 receptor | I/II | NCT03441048 NCT03867682 |
Gentuzumab Ozogamicin | Newly diagnosed and relapsed AML | MoAb | Leads to cell death by causing site-specific, double-stranded breaks | II | NCT03374332 | |
AMG330 | AML | BiTE | Directs cytotoxic T cells to CD33-expressed human AML cells killing the target | I | NCT02520427 | |
JNJ-67571244 | Not responding AML patients at high risk of myelodysplastic syndrome | BiTE | Directs cytotoxic T cells to CD33-expressed human AML cells killing the target | I | NCT03915379 | |
CD33 CAR-T | AML | CAR T | T-cells are genetically changed to help target leukemia cells | I/II | NCT03126864 | |
Siglec 6 | Siglec-6 CAR-T | CLL | CAR T | Increases the activity of CARs that target membrane-distal epitopes | Not Applicable | [23] |
Siglec 7 | Ganglioside GD3 | Melanoma | Vaccine | Modulate NK cell cytotoxicity | Not Applicable | NCT00597272 |
Siglec-7 CAR-T | Solid Tumors | CAR T | Recognizes and eliminates tumor cells, in a non‐ histocompatibility complex molecule restricted way | Not Applicable | [74] | |
Siglec 9 | Gatipotuzumab | Solid Tumors | MoAb | Activats the immune system to induce ADCC agains tumor cells | I/II | NCT01222624 NCT03360734 |
Siglec-9 CAR-T | Solid Tumors | CAR T | Recognizes and eliminates tumor cells, in a non‐ histocompatibility complex molecule restricted way | Not Applicable | [74] | |
Siglec 10 | Alemtuzumab | CLL | MoAb | Kills of tumour cells by CDC and ADCC | II | NCT01465334 |
Siglec 15 | NC318 | Advanced or metastatic solid tumors | MoAb | Restores normal T-cell function by blocking Siglec-15-mediated immunosuppression | I/II | NCT03665285 |